Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma

Journal of Allergy and Clinical Immunology

Volumn 98, Issue 3, 1996, Pages 528-534

  Reiss, Theodore F ^a   Altman, Leonard C ^b   Chervinsky, Paul ^c   Bewtra, Againdra ^d   Stricker, William E ^e   Noonan, Gertrude P ^a   Kundu, Sudeep ^a   Zhang, Ji ^f  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Pacific Medical Centers   (United States)

^c Allergy and Asthma Center   (United States)

^d CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Clinical Research of the Ozarks   (United States)

^f Merck Research Laboratories ^*

Author keywords

Bronchodilation; Cysteinyl leukotriene receptor antagonist; Montelukast (MK 0476)

Indexed keywords

BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; SALBUTAMOL; TRIAMCINOLONE;

ADULT; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LABORATORY TEST; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPIROMETRY; THORAX RADIOGRAPHY;

ACETATES; ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; ASTHMA; CHRONIC DISEASE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENE D4; MALE; MEMBRANE PROTEINS; MIDDLE AGED; QUINOLINES; RECEPTORS, LEUKOTRIENE;

EID: 0029970797     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-6749(96)70086-6     Document Type: Article

References (17)

1. Parker SR, Mellins RB, Sogn DD. Asthma education: a national strategy. Am Rev Respir Dis 1989;140:848-53.
2. Dahlen SE, Hedquist P, Hammerstrom B, Samuelsson B. Leukotrienes are potent constrictors of human bronchii. Nature 1980;288:484-6.
3. Woodward DF, Weichman BM, Gill CA, Wasserman MA. The effect of synthetic leukotrienes on tracheal microvascular permeability. Prostaglandins 1983;25:131.
4. Marom Z, Shelhammer JH, Bach MK, Morton DR, Kaliner M. Slow reacting substances LTC4 and D4 increase the release of mucus from human airways in vitro. Am Rev Respir Dis 1982;126:449-51.
5. Rasmussen JB, Eriksson LO, Margolskee DJ, Tagari P, Williams V, Anderson KE. Leukotriene D4-receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma. J Allergy Clin Immunol 1992;90:193-201.
6. Manning PJ, Watson RM, Margolskee DJ, Williams V, Schwartz J, O'Byrne PM. Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist. N Engl J Med 1990;323:1736-9.
7. Dahlen B, Kumlin M, Johansson H, et al. The leukotriene antagonist MK-0679 improves baseline pulmonary function and blocks aspirin-induced airway obstruction in aspirin-sensitive asthmatics [abstract]. Am Rev Respir Dis 1992;145:A15.
8. Impens N, Reiss TF, Teahan JA, et al. MK-0679, acute bronchodilation with an intravenously administered leukotriene D4 antagonist, MK-679. Am Rev Respir Dis 1993; 147:1442-6.
9. 4) receptor antagonist (MK-571) in patients with asthma. Am Rev Respir Dis 1992;146:358-63.
10. Margolskee DJ, Bodman S, Dockhorn R, et al. The therapeutic effects of MK-571, a potent and selective leukotriene (LT) D4 receptor antagonist, in patients with chronic asthma [abstract]. J Allergy Clin Immunol 1991;87:309.
11. 4 receptor antagonist. Can J Physiol Pharmacol 1995;73:191-201.
12. 4 receptor antagonism in the airways of asthmatics [abstract]. Am J Respir Crit Care Med 1994;149:A465.
13. Santanello NC, Barber BL, Friedman B, Reiss TF, Zhang J. Measurement characteristics of three asthma symptom diaries validated in three separate studies of mild to moderate asthma patients [abstract]. Am Rev Respir Crit Care Med 1994;149:A917.
14. Hong SL, Levine L. Inhibition of arachidonic acid release from cells as the biochemical action of antiinflammatory corticosteroids. Proc Natl Acad Sci USA 1976;73:1730-4.
15. Dworski R, Fitzgerald GA, Oayr JA, Sheller JL. Effect of oral prednisone on airways inflammatory mediators in atopic disease. Am J Respir Crit Care Med 1994;449:953-9.
16. Spector SL, Smith LJ, Glass M, and the Accolate Asthma Trialist Group. Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. J Respir Crit Care Med 1994;150:618-23.
17. Israel E, Rubin P, Kemp JP, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med 1993;119:1059-1066.